Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hoth options GWU's aprepitant patents for dermatological side effects of erlotinib

Executive Summary

Following a sponsored research agreement announced last month, Hoth Therapeutics Inc. signed a definitive agreement with George Washington University, gaining an exclusive option to the latter's patents (Nos. 9,474,761 and 9,687,493) related to methods of using aprepitant or other neurokinin-1 (NK-1) receptor antagonists for topical and/or systemic therapy to address dermatological-related side effects of erlotinib in cancer patients.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies